Clinical Experience on 225Ac-PSMA-617 Targeted Alpha Therapy in Metastatic Castration Resistant Prostate Cancer Patients: Safety and Efficacy Results

被引：0
|
作者：
Yadav, Madhav [1 ]
Ballal, Sanjana [1 ]
Bal, Chandrasekhar [1 ]
Tripathi, Madhavi [1 ]
机构：
[1] All India Inst Med Sci, Nucl Med, New Delhi, India
来源：
JOURNAL OF NUCLEAR MEDICINE | 2020年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
589
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Optimizing the treatment regimen for targeted alpha therapy of mCRPC with 225Ac-PSMA-617
    Kratochwil, C.
    Rathke, H.
    Bruchertseifer, F.
    Giesel, F. L.
    Haberkorn, U.
    Morgenstern, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S54 - S54
  • [32] Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA
    Tauber, R. L.
    Feuerecker, B.
    Knorr, K.
    Beheshti, A.
    Seidl, C.
    D'Alessandria, C.
    Bruchertseifer, F.
    Retz, M.
    Gschwend, J. E.
    Weber, W.
    Morgenstern, A.
    Eiber, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [33] 225Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis
    Ballal, Sanjana
    Yadav, Madhav P.
    Sahoo, Ranjit K.
    Tripathi, Madhavi
    Dwivedi, Sada N.
    Bal, Chandrasekhar
    PROSTATE, 2021, 81 (09): : 580 - 591
  • [34] Relative Efficacy of 225Ac-PSMA-617 and 117Lu-PSMA-617 in Prostate Cancer Based on Subcellular Dosimetry
    Lee, Hwan
    MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, 2022, 31 (01) : 1 - 6
  • [35] Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Bal, Chandrashekhar
    Sahoo, Ranjit Kumar
    Damle, Nishikant Avinash
    Tripathi, Madhavi
    Seth, Amlesh
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (01) : 19 - 31
  • [36] CKD After 225Ac-PSMA617 Therapy in Patients With Metastatic Prostate Cancer
    Pelletier, Karyne
    Cote, Gabrielle
    Fallah-Rad, Nazanin
    John, Rohan
    Kitchlu, Abhijat
    KIDNEY INTERNATIONAL REPORTS, 2021, 6 (03): : 853 - 856
  • [37] Simple method for production and quality control of 225Ac- PSMA-617 for the targeted alpha therapy of castration-resistant prostate cancer.
    Khoshhosn, H.
    Dayeni, M.
    Pirdadeh, M.
    Ghapanvari, M.
    Tavakoli, Y.
    Samizadeh, M.
    Mazidi, M.
    Nami, R.
    Soltani, N.
    Movahhed, H.
    Gravand, A.
    Sarabi, A.
    Davarpanah, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S674 - S675
  • [38] PSMA Radioligand Therapy (PRLT) of Metastatic Castration-Resistant Prostate Cancer: Safety, Efficacy and Dosimetry using the PSMA Inhibitor 617
    Kulkarni, H. R.
    Schuchardt, C.
    Singh, A.
    Niepsch, K.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S139 - S139
  • [39] 225Ac-PSMA-617 Radioligand Posttherapy Imaging in Metastatic Castrate-Resistant Prostate Cancer Patient Using 3 Photopeaks
    Vatsa, Rakhee
    Sood, Ashwani
    Vadi, Shelvin Kumar
    Das, Chandan Krushna
    Kaur, Komalpreet
    Parmar, Madan
    Mittal, Bhagwant Rai
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (06) : 437 - 438
  • [40] 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
    Sathekge, Mike
    Bruchertseifer, Frank
    Knoesen, Otto
    Reyneke, Florette
    Lawal, Ismaheel
    Lengana, Thabo
    Davis, Cindy
    Mahapane, Johncy
    Corbett, Ceceila
    Vorster, Mariza
    Morgenstern, Alfred
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (01) : 129 - 138
12345